Summary The International Myeloma Working Group consensus aimed to provide
recommendations for the optimal use of 18 fluorodeoxyglucose (18 F-FDG) PET/CT in …

Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a
single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In …

Background Sinonasal neoplasms, whether benign and malignant, pose a significant
challenge to clinicians and represent a model area for multidisciplinary collaboration in …

Solitary plasmacytoma is a rare disease characterized by a localized proliferation of
neoplastic monoclonal plasma cells, without evidence of systemic disease. It can be …

Recent innovative strategies have dramatically redefined the therapeutic landscape for
treating multiple myeloma patients. In particular, the development and application of …

Recent advances in the diagnosis and treatment of multiple myeloma (MM) have highlighted
the importance of imaging methods, not only in the localization and extent of the disease but …

The novel criteria for the diagnosis of symptomatic multiple myeloma have revealed the
value of modern imaging for the management of patients with myeloma. Whole-body low …

Imaging in hematological diseases has evolved extensively over the past several decades.
Positron emission tomography/computed tomography (PET/CT) with of 2-[18 F]-fluoro-2 …

The interest of 18Fluoro-deoxyglucose (FDG) positron emission tomography (PET) imaging
in the management of patients with multiple myeloma (MM) for the workup at diagnosis and …

Purpose Solitary plasmacytoma (SP) is a rare plasma-cell neoplasm, which can develop
both in skeletal and/or soft tissue and frequently progresses to multiple myeloma (MM). Our …